Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,970 | 8-10 weeks | |
50 mg | $2,580 | 8-10 weeks | |
100 mg | $3,400 | 8-10 weeks |
Description | EVT801 is an orally active, selective VEGFR-3 inhibitor (IC 50 = 11 nM) with demonstrated antitumor properties. It effectively suppresses VEGF-C-induced human endothelial cell proliferation and tumor (lymphatic) angiogenesis in mouse models. Moreover, EVT801 reduces tumor hypoxia and the production of immunosuppressive cytokines (CCL4, CCL5) and myeloid-derived suppressor cells (MDSC), enhancing the efficacy of immune checkpoint therapy (ICT). This synergy results in improved ICT response rates and more potent anticancer effects in cancer mouse models. |
Molecular Weight | 367.4 |
Formula | C19H21N5O3 |
Cas No. | 1412453-70-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.